Search Results
University of Alabama at Birmingham, Department of Surgery, Division of Surgical Oncology, Birmingham, Alabama, USA
Search for other papers by Sarah B Bateni in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Natalie G Coburn in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Search for other papers by Calvin Law in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Simron Singh in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Angela Assal in
Google Scholar
PubMed
Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Clinical evaluative sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada
Search for other papers by Julie Hallet in
Google Scholar
PubMed
K Byers LA Sorbye H & Yao JC 2018 Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases . Cancer 124 807 – 815 . ( https://doi.org/10.1002/cncr.31124
Search for other papers by Takaya Kodama in
Google Scholar
PubMed
Search for other papers by Kenji Oki in
Google Scholar
PubMed
Search for other papers by Yu Otagaki in
Google Scholar
PubMed
Search for other papers by Ryuta Baba in
Google Scholar
PubMed
Search for other papers by Akira Okada in
Google Scholar
PubMed
Search for other papers by Kiyotaka Itcho in
Google Scholar
PubMed
Search for other papers by Kazuhiro Kobuke in
Google Scholar
PubMed
Search for other papers by Gaku Nagano in
Google Scholar
PubMed
Search for other papers by Haruya Ohno in
Google Scholar
PubMed
Search for other papers by Nobuyuki Hinata in
Google Scholar
PubMed
Search for other papers by Koji Arihiro in
Google Scholar
PubMed
Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA
Search for other papers by Celso E Gomez-Sanchez in
Google Scholar
PubMed
Search for other papers by Masayasu Yoneda in
Google Scholar
PubMed
Search for other papers by Noboru Hattori in
Google Scholar
PubMed
.1016/j.humpath.2016.03.016 ) 27085553 10.1016/j.humpath.2016.03.016 La Rosa S Furlan D Franzi F Battaglia P Frattini M Zanellato E Marando A Sahnane N Turri-Zanoni M Castelnuovo P , 2013 Mixed exocrine-neuroendocrine carcinoma of
Search for other papers by G Butturini in
Google Scholar
PubMed
Search for other papers by R Bettini in
Google Scholar
PubMed
Search for other papers by E Missiaglia in
Google Scholar
PubMed
Search for other papers by W Mantovani in
Google Scholar
PubMed
Search for other papers by I Dalai in
Google Scholar
PubMed
Search for other papers by P Capelli in
Google Scholar
PubMed
Search for other papers by M Ferdeghini in
Google Scholar
PubMed
Search for other papers by P Pederzoli in
Google Scholar
PubMed
Search for other papers by A Scarpa in
Google Scholar
PubMed
Search for other papers by M Falconi in
Google Scholar
PubMed
gastroenteropancreatic neuroendocrine carcinomas, only nine reports included NF-PEC (Table 3 ). A total of 68 NF-PEC have been treated with octreotide or lanreotide, but follow-up data are available only for 18 patients ( di Bartolomeo et al. 1996 , Angeletti et al
Search for other papers by Kenzo Nakano in
Google Scholar
PubMed
Search for other papers by Toshihiko Masui in
Google Scholar
PubMed
Search for other papers by Akitada Yogo in
Google Scholar
PubMed
Search for other papers by Yuichiro Uchida in
Google Scholar
PubMed
Search for other papers by Asahi Sato in
Google Scholar
PubMed
Search for other papers by Yosuke Kasai in
Google Scholar
PubMed
Search for other papers by Kazuyuki Nagai in
Google Scholar
PubMed
Search for other papers by Takayuki Anazawa in
Google Scholar
PubMed
Search for other papers by Yoshiya Kawaguchi in
Google Scholar
PubMed
Search for other papers by Shinji Uemoto in
Google Scholar
PubMed
-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinoma (PanNEC). Although pancreatic adenocarcinoma (PDAC) has a very dismal clinical prognosis, PanNENs have been regarded as relatively indolent. However
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by David P Ryan in
Google Scholar
PubMed
Search for other papers by Andrew X Zhu in
Google Scholar
PubMed
Search for other papers by Thomas A Abrams in
Google Scholar
PubMed
Search for other papers by Brian M Wolpin in
Google Scholar
PubMed
Search for other papers by Paige Malinowski in
Google Scholar
PubMed
Search for other papers by Eileen M Regan in
Google Scholar
PubMed
Search for other papers by Charles S Fuchs in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
histologically documented, locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors of low grade or intermediate histological grade. Patients with poorly differentiated or high-grade neuroendocrine carcinomas were not eligible. Treatment
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by M Ghayouri in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by M Brelsford in
Google Scholar
PubMed
Search for other papers by M Black in
Google Scholar
PubMed
Search for other papers by A Rizzo in
Google Scholar
PubMed
Search for other papers by A Meeker in
Google Scholar
PubMed
Search for other papers by J Strosberg in
Google Scholar
PubMed
males, and more than three quarters (115/143) had grade 1 or 2 pNETs. No large cell or small cell neuroendocrine carcinomas were included in the study. Twenty-seven patients had hormonally functioning tumors, including 11 patients with gastrinoma
Search for other papers by Andreas Machens in
Google Scholar
PubMed
Search for other papers by Florian Hoffmann in
Google Scholar
PubMed
Search for other papers by Carsten Sekulla in
Google Scholar
PubMed
Search for other papers by Henning Dralle in
Google Scholar
PubMed
patients by quantitative lymph node analysis . Cancer 88 1909 – 1915 . Machens A Haedecke J Holzhausen HJ Thomusch O Schneyer U Dralle H 2000b Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by
Search for other papers by Ta-Chun Yuan in
Google Scholar
PubMed
Search for other papers by Suresh Veeramani in
Google Scholar
PubMed
Search for other papers by Ming-Fong Lin in
Google Scholar
PubMed
, Caprioli RM, Tsukamoto T, Shappell SB & Matusik RJ 2001 A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research 61 2239 –2249
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Elke Tatjana Aristizabal Prada in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Vera Heinzle in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Thomas Knösel in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Julian Maurer in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Christine Spitzweg in
Google Scholar
PubMed
Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Martin Angele in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Nina Schmidt in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Rainer Blaser in
Google Scholar
PubMed
Search for other papers by Klaus A Kuhn in
Google Scholar
PubMed
Department of Internal Medicine 2, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Department of Internal Medicine 4, University-Hospital, Klinikum der Universität München, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
al . 2017 ). In a large-cell neuroendocrine carcinoma (LCNEC) cell line the pan-Trk inhibitor AZD7451 showed promising pharmacologic potential, particularly in cells with a NTRK gene fusion with constitutive Trk expression ( Tatematsu et al . 2014
Search for other papers by Thomas J Giordano in
Google Scholar
PubMed
, supported by mouse studies, provides evidence that NOTCH functions as a tumor suppressor and master regulator of NE differentiation in SCLC. Skin neuroendocrine tumors Primary cutaneous neuroendocrine carcinoma, termed Merkel cell carcinoma (MCC